indazoles has been researched along with regorafenib in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 14 (77.78) | 24.3611 |
| 2020's | 4 (22.22) | 2.80 |
| Authors | Studies |
|---|---|
| Goh, V; Gore, M; Juttla, JK; Larkin, JM; Nathan, PD; Reynolds, AR; Thompson, VL; Vasudev, NS | 1 |
| Liang, H | 1 |
| Afonso, R; Angeles, C; Campos, JM; García-Alfonso, P; Grande, E; Jorge, M; Martínez, V; Montagut, C; Polo, E; Reina, JJ | 1 |
| Abdel-Rahman, O; Fouad, M | 1 |
| Badalamenti, G; Baldi, GG; Casali, PG; Cominetti, D; Dagrada, GP; Dei Tos, AP; Festinese, F; Fumagalli, E; Grignani, G; Gronchi, A; Morosi, C; Negri, T; Pennacchioli, E; Pilotti, S; Provenzano, S; Spagnuolo, RD; Stacchiotti, S; Tortoreto, M; Toss, A; Zaffaroni, N | 1 |
| Booth, L; Cruz-Luna, T; Cycon, KA; Dent, P; Doern, CD; Fidanza, A; Nourbakhsh, A; Plamondon, P; Roberts, JL; Siembida, P; Smith, E; Tavallai, M | 1 |
| Burns, K; Knights, KM; Mackenzie, PI; Miners, JO; Nair, PC; Rowland, A | 1 |
| Alexandre, J; Arrondeau, J; Blanchet, B; Boudou-Rouquette, P; Bretagne, M; Cabanes, L; Cessot, A; Chahwakilian, A; Coriat, R; Goldwasser, F; Huillard, O; Orvoen, G; Thomas-Schoemann, A; Tlemsani, C | 1 |
| Burns, K; Chau, N; Kichenadasse, G; Knights, KM; Mackenzie, PI; McKinnon, RA; Miners, JO; Rowland, A; Tucker, GT | 1 |
| Gu, J; Li, J | 1 |
| Joussen, AM; Zeitz, O | 1 |
| Ativitavas, T; Kongsuphon, N; Konmun, J; Ngamphaiboon, N; Soukavanitch, M; Teeraaumpornpunt, N | 1 |
| Buclin, T; Cagnon, L; Cardoso, E; Csajka, C; Decosterd, L; Diezi, M; Ellefsen-Lavoie, K; Homicsko, K; Mercier, T; Michielin, O; Wagner, AD; Widmer, N | 1 |
| Haniuda, H; Horita, S; Kagawa, Y; Katagiri, M; Nakamura, H; Nakazato, T; Watanabe, M | 1 |
| Bertucci, F; Blay, JY; Bompas, E; Brodowicz, T; Chaigneau, L; Chevreau, C; Decoupigny, E; Delcambre, C; Italiano, A; Laroche, L; Le Cesne, A; Le Deley, MC; Mir, O; Penel, N; Ray-Coquard, I; Saada-Bouzid, E; Salas, S; Taieb, S; Vanseymortier, M; Wallet, J | 1 |
| Gomes, A; Mankoski, R; Miller, A; Nellesen, D; Norregaard, C; Proudman, D; Sullivan, E | 1 |
| Bria, E; Cintoni, M; Gasbarrini, A; Mele, MC; Pompili, M; Ponziani, FR; Pozzo, C; Raoul, P; Rinninella, E; Strippoli, A; Tortora, G | 1 |
| Amani, AM; Dehaen, W; Ramezanpour, S; Shiri, P | 1 |
7 review(s) available for indazoles and regorafenib
| Article | Year |
|---|---|
The role of antiangiogenic agents in the treatment of patients with advanced colorectal cancer according to K-RAS status.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; ErbB Receptors; Fluorouracil; Genes, ras; Humans; Imidazoles; Indazoles; Indoles; Irinotecan; Niacinamide; Oligonucleotides; Organoplatinum Compounds; Oxaliplatin; Pharmacogenetics; Phenylurea Compounds; Prognosis; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Signal Transduction; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2014 |
Risk of cardiovascular toxicities in patients with solid tumors treated with sunitinib, axitinib, cediranib or regorafenib: an updated systematic review and comparative meta-analysis.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Axitinib; Cardiovascular Diseases; Humans; Imidazoles; Incidence; Indazoles; Indoles; Neoplasms; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Risk; Sunitinib | 2014 |
[Tyrosine kinase inhibiting the VEGF pathway and elderly people: Tolerance, pre-treatment assessment and side effects management].
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Axitinib; Fatigue; Humans; Imidazoles; Indazoles; Indoles; Kidney; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib | 2016 |
Fatigue associated with newly approved vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: an up-to-date meta-analysis.
Topics: Anilides; Axitinib; Fatigue; Humans; Imidazoles; Indazoles; Neoplasms; Odds Ratio; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quinolines; Receptors, Vascular Endothelial Growth Factor | 2017 |
[Eye Drops Instead of Intravitreal Injections? The Dream of Treating Macular Diseases by Topically Administered Drugs].
Topics: Algorithms; Cholestanols; Double-Blind Method; Indazoles; Indoles; Intravitreal Injections; Ophthalmic Solutions; Phenylurea Compounds; Pyrazoles; Pyridines; Pyrimidines; Randomized Controlled Trials as Topic; Sulfonamides; Vascular Endothelial Growth Factor A; Wet Macular Degeneration | 2017 |
Prognostic value of skeletal muscle mass during tyrosine kinase inhibitor (TKI) therapy in cancer patients: a systematic review and meta-analysis.
Topics: Gefitinib; Humans; Imatinib Mesylate; Indazoles; Muscle, Skeletal; Neoplasms; Phenylurea Compounds; Prognosis; Pyrazoles; Pyridines; Pyrimidines; Quinolines; Sorafenib; Sulfonamides; Sunitinib; Survival Analysis | 2021 |
A patent review on efficient strategies for the total synthesis of pazopanib, regorafenib and lenvatinib as novel anti-angiogenesis receptor tyrosine kinase inhibitors for cancer therapy.
Topics: Humans; Indazoles; Neoplasms; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Quinolines; Sulfonamides; Tyrosine | 2022 |
2 trial(s) available for indazoles and regorafenib
| Article | Year |
|---|---|
Preclinical and clinical evidence of activity of pazopanib in solitary fibrous tumour.
Topics: Administration, Oral; Adult; Aged; Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Axitinib; Bevacizumab; Humans; Imidazoles; Indazoles; Indoles; Male; MAP Kinase Signaling System; Mice, SCID; Middle Aged; Neoplasm Transplantation; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor beta; Solitary Fibrous Tumors; Sorafenib; Sulfonamides; Sunitinib; Transplantation, Heterologous; Vascular Endothelial Growth Factor Receptor-2 | 2014 |
A double-blind placebo-controlled randomized phase II trial assessing the activity and safety of regorafenib in non-adipocytic sarcoma patients previously treated with both chemotherapy and pazopanib.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chest Pain; Cross-Over Studies; Diarrhea; Disease Progression; Double-Blind Method; Female; Humans; Indazoles; Kaplan-Meier Estimate; Leukopenia; Male; Middle Aged; Phenylurea Compounds; Pyridines; Pyrimidines; Sarcoma; Soft Tissue Neoplasms; Sulfonamides; Treatment Outcome | 2020 |
9 other study(ies) available for indazoles and regorafenib
| Article | Year |
|---|---|
Changes in tumour vessel density upon treatment with anti-angiogenic agents: relationship with response and resistance to therapy.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Biomarkers, Tumor; Blood Vessels; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neovascularization, Pathologic; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sulfonamides; Sunitinib | 2013 |
[Treatment strategy for recurrent and metastatic gastrointestinal stromal tumors].
Topics: Benzamides; Disease-Free Survival; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Hepatectomy; Humans; Imatinib Mesylate; Indazoles; Indoles; Liver Neoplasms; Phenylurea Compounds; Piperazines; Pyridines; Pyrimidines; Pyrroles; Recurrence; Sulfonamides; Sunitinib | 2014 |
GRP78/Dna K Is a Target for Nexavar/Stivarga/Votrient in the Treatment of Human Malignancies, Viral Infections and Bacterial Diseases.
Topics: Animals; Bacterial Infections; Cell Line, Tumor; Endoplasmic Reticulum Chaperone BiP; Escherichia coli; Heat-Shock Proteins; Humans; Indazoles; Neoplasms; Niacinamide; Phenylurea Compounds; Polynucleotide 5'-Hydroxyl-Kinase; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Sorafenib; Sulfonamides; Virus Diseases | 2015 |
The Nonspecific Binding of Tyrosine Kinase Inhibitors to Human Liver Microsomes.
Topics: Humans; Indazoles; Microsomes, Liver; Niacinamide; Phenylurea Compounds; Protein Binding; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Sorafenib; Sulfonamides | 2015 |
Inhibition of human UDP-glucuronosyltransferase enzymes by lapatinib, pazopanib, regorafenib and sorafenib: Implications for hyperbilirubinemia.
Topics: Bilirubin; Catalysis; Enzyme Inhibitors; Glucuronosyltransferase; Humans; Hyperbilirubinemia; Indazoles; Kinetics; Lapatinib; Microsomes, Liver; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Quinazolines; Sorafenib; Sulfonamides | 2017 |
Multi-Targeted Tyrosine Kinase Inhibitor-Induced Hyperammonemic Encephalopathy: a Report of Two Cases Using Pazopanib, Sunitinib, and Regorafenib.
Topics: Aged; Ammonia; Anti-Bacterial Agents; Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Female; Gastrointestinal Stromal Tumors; Humans; Hyperammonemia; Indazoles; Middle Aged; Neurotoxicity Syndromes; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Sulfonamides; Sunitinib; Treatment Outcome; Withholding Treatment | 2019 |
Quantification of the next-generation oral anti-tumor drugs dabrafenib, trametinib, vemurafenib, cobimetinib, pazopanib, regorafenib and two metabolites in human plasma by liquid chromatography-tandem mass spectrometry.
Topics: Administration, Oral; Antineoplastic Agents; Azetidines; Child; Chromatography, High Pressure Liquid; Humans; Imidazoles; Indazoles; Indoles; Limit of Detection; Linear Models; Oximes; Phenylurea Compounds; Piperidines; Pyridines; Pyridones; Pyrimidines; Pyrimidinones; Reproducibility of Results; Sulfonamides; Tandem Mass Spectrometry; Vemurafenib | 2018 |
Species differences in ocular pharmacokinetics and pharmacological activities of regorafenib and pazopanib eye-drops among rats, rabbits and monkeys.
Topics: Angiogenesis Inhibitors; Animals; Choroidal Neovascularization; Crystallization; Disease Models, Animal; Drug Evaluation, Preclinical; Eye; Female; Humans; Indazoles; Macaca fascicularis; Macular Degeneration; Male; Nanoparticles; Ophthalmic Solutions; Particle Size; Phenylurea Compounds; Pyridines; Pyrimidines; Rabbits; Rats; Receptors, Vascular Endothelial Growth Factor; Species Specificity; Sulfonamides; Vascular Endothelial Growth Factor A | 2019 |
Financial Implications of Avapritinib for Treatment of Unresectable Gastrointestinal Stromal Tumors in Patients With a PDGFRA Exon 18 Variant or After 3 Previous Therapies in a Hypothetical US Health Plan.
Topics: Antineoplastic Agents; Budgets; Cost-Benefit Analysis; Formularies as Topic; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indazoles; Managed Care Programs; Medicaid; Medicare; Molecular Diagnostic Techniques; Phenylurea Compounds; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Sulfonamides; Sunitinib; Treatment Failure; Triazines; United States | 2020 |